Coverage of the system, the seed round, and what an autonomous fill means for the people behind the counter.
Queue, the company building the world's first fully autonomous robotic pharmacy, today emerged from stealth with a working system designed to transform how prescriptions are dispensed, verified, and delivered.
The company recently closed an oversubscribed $12.6 million seed round led by AlleyCorp, following a $6 million pre-seed round led by Riot Ventures less than a year ago, bringing Queue's total funding to $18.6 million. Additional investors include House Capital, Ubiquity Ventures, Grep Ventures, and Banter Capital.
Queue is entering the market at a critical moment for American pharmacy. More than 4,000 pharmacies closed in 2025, with one in four pharmacy jobs remaining unfilled. Major chains currently lose money on every prescription filled — leaving a $55 billion market under structural pressure with few viable paths forward.
Queue's fully autonomous robotic pharmacy was built to change that by making prescription fulfillment faster, easier to access, and more cost-effective while maintaining rigorous safety and verification protocols. The system can be seen in action here.
Operating autonomously, Queue's system takes sealed wholesale pill bottles in one end and produces filled, verified prescription vials out the other. The platform currently supports 250 of the most commonly prescribed medications in the United States.
“Pharmacy in America is structurally broken. Queue isn't an incremental fix; it's a complete reimagining of how medications get dispensed, verified, and delivered. We built the machine the industry has needed for decades, and the demand we're seeing proves it.”Josh Liu, Co-Founder & CTO
The result is a fundamentally different model for prescription fulfillment. Queue can deliver medications at up to 96% lower cost than traditional pharmacy operations and can be deployed across retail locations, hospitals, rural communities, and other care settings where pharmacy access is constrained.
Queue has already secured a major national pharmacy chain as a customer and deployed a working prototype, giving the company early commercial validation in a market faced with urgent labor, cost, and access challenges.
“What the Queue team has accomplished is rare in the development of hardware for healthcare. We decided to lead this funding round because we believe Queue is building critical infrastructure that can both increase accessibility for patients to get the prescriptions they need, while using robotics and automation to greatly improve labor constraints that exist across pharmacies.”Abe Murray, General Partner, AlleyCorp
“Pharmacy has an infrastructure problem. While the industry has been forced to work around labor shortages, store closures, and broken unit economics, Nick and Josh have taken a fundamentally different approach: automating the physical fulfillment layer itself. Queue is exactly the kind of company Riot backs early — exceptional founders solving a massive, urgent problem with technology that can deliver outsized impact.”Will Coffield, Partner, Riot Ventures
Queue was co-founded by Nick Desai, CEO, a six-time venture-backed entrepreneur who previously built a company acquired by Humana in a nine-figure exit, and Josh Liu, CTO, whose experience spans Tesla and Zipline.
The funding will be used to accelerate product development, expand deployments with enterprise pharmacy customers, and grow Queue's engineering team. Queue currently has a team of 20 engineers in Silicon Valley and is actively hiring across robotics, hardware, software, and pharmacy operations.
As pharmacy deserts expand, labor shortages persist, and traditional pharmacy economics continue to break down, Queue is positioning autonomous prescription fulfillment as a new infrastructure layer for American healthcare — enabling pharmacy services to move closer to patients with dramatically better economics.
Retail chains, health systems and independents: talk to our team about putting a unit behind your counter.